Long-term impact of secondary preventive treatments in patients with stable angina

Z. Vokó, Sophie De Brouwer, Jacobus Lubsen, Nicolas Danchin, Jan Erik Otterstad, Peter H J M Dunselman, Bridget Anne Kirwan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We assessed the independent effects of beta blockers, calcium antagonists, lipid-lowering drugs, angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), anti-platelet drugs, vitamin K antagonists, percutaneous coronary intervention (PCI) and coronary artery by-pass grafting (CABG) on mortality and on the composite endpoint of death, myocardial infarction, stroke or heart failure in patients with stable angina pectoris. We estimated the effects of the interventions used at baseline by multivariate Cox regression and during follow-up by G-estimation in 7,665 patients followed for a mean of 5 years in the ACTION trial. Adjusted hazard ratios (95% confidence intervals) comparing all cause mortality among users during follow-up to non-users were 1.01 (0.91, 1.09) for beta blockade, 0.82 (0.75, 0.89) for ACEIs or ARBs, 0.93 (0.87, 0.98) for calcium antagonists, 0.54 (0.49, 0.62) for lipid-lowering drugs, 0.49 (0.42, 0.53) for anti-platelet drugs, 0.74 (0.69, 0.78) for PCI, and 0.91 (0.82, 0.98) for CABG. Effects on the composite endpoint were less marked. This observational study confirms that ACEIs or ARBs, lipid-lowering and anti-platelet drugs as used in the everyday management of stable angina have independent secondary preventive effects. Calcium antagonists, PCI and CABG also appear to improve outcome.

Original languageEnglish
Pages (from-to)375-383
Number of pages9
JournalEuropean Journal of Epidemiology
Volume26
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Stable Angina
Angiotensin Receptor Antagonists
Percutaneous Coronary Intervention
Angiotensin-Converting Enzyme Inhibitors
Coronary Vessels
Pharmaceutical Preparations
Blood Platelets
Calcium
Lipids
Therapeutics
Vitamin K
Mortality
Observational Studies
Heart Failure
Stroke
Myocardial Infarction
Confidence Intervals

Keywords

  • Angina pectoris
  • Cardiovascular agents
  • Coronary artery bypass
  • Coronary disease
  • G-estimation
  • Percutaneous coronary intervention
  • Secondary prevention

ASJC Scopus subject areas

  • Epidemiology

Cite this

Vokó, Z., De Brouwer, S., Lubsen, J., Danchin, N., Otterstad, J. E., Dunselman, P. H. J. M., & Kirwan, B. A. (2011). Long-term impact of secondary preventive treatments in patients with stable angina. European Journal of Epidemiology, 26(5), 375-383. https://doi.org/10.1007/s10654-011-9558-5

Long-term impact of secondary preventive treatments in patients with stable angina. / Vokó, Z.; De Brouwer, Sophie; Lubsen, Jacobus; Danchin, Nicolas; Otterstad, Jan Erik; Dunselman, Peter H J M; Kirwan, Bridget Anne.

In: European Journal of Epidemiology, Vol. 26, No. 5, 05.2011, p. 375-383.

Research output: Contribution to journalArticle

Vokó, Z, De Brouwer, S, Lubsen, J, Danchin, N, Otterstad, JE, Dunselman, PHJM & Kirwan, BA 2011, 'Long-term impact of secondary preventive treatments in patients with stable angina', European Journal of Epidemiology, vol. 26, no. 5, pp. 375-383. https://doi.org/10.1007/s10654-011-9558-5
Vokó, Z. ; De Brouwer, Sophie ; Lubsen, Jacobus ; Danchin, Nicolas ; Otterstad, Jan Erik ; Dunselman, Peter H J M ; Kirwan, Bridget Anne. / Long-term impact of secondary preventive treatments in patients with stable angina. In: European Journal of Epidemiology. 2011 ; Vol. 26, No. 5. pp. 375-383.
@article{86d33f6a08f847e8870ca6109b6195c3,
title = "Long-term impact of secondary preventive treatments in patients with stable angina",
abstract = "We assessed the independent effects of beta blockers, calcium antagonists, lipid-lowering drugs, angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), anti-platelet drugs, vitamin K antagonists, percutaneous coronary intervention (PCI) and coronary artery by-pass grafting (CABG) on mortality and on the composite endpoint of death, myocardial infarction, stroke or heart failure in patients with stable angina pectoris. We estimated the effects of the interventions used at baseline by multivariate Cox regression and during follow-up by G-estimation in 7,665 patients followed for a mean of 5 years in the ACTION trial. Adjusted hazard ratios (95{\%} confidence intervals) comparing all cause mortality among users during follow-up to non-users were 1.01 (0.91, 1.09) for beta blockade, 0.82 (0.75, 0.89) for ACEIs or ARBs, 0.93 (0.87, 0.98) for calcium antagonists, 0.54 (0.49, 0.62) for lipid-lowering drugs, 0.49 (0.42, 0.53) for anti-platelet drugs, 0.74 (0.69, 0.78) for PCI, and 0.91 (0.82, 0.98) for CABG. Effects on the composite endpoint were less marked. This observational study confirms that ACEIs or ARBs, lipid-lowering and anti-platelet drugs as used in the everyday management of stable angina have independent secondary preventive effects. Calcium antagonists, PCI and CABG also appear to improve outcome.",
keywords = "Angina pectoris, Cardiovascular agents, Coronary artery bypass, Coronary disease, G-estimation, Percutaneous coronary intervention, Secondary prevention",
author = "Z. Vok{\'o} and {De Brouwer}, Sophie and Jacobus Lubsen and Nicolas Danchin and Otterstad, {Jan Erik} and Dunselman, {Peter H J M} and Kirwan, {Bridget Anne}",
year = "2011",
month = "5",
doi = "10.1007/s10654-011-9558-5",
language = "English",
volume = "26",
pages = "375--383",
journal = "European Journal of Epidemiology",
issn = "0393-2990",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Long-term impact of secondary preventive treatments in patients with stable angina

AU - Vokó, Z.

AU - De Brouwer, Sophie

AU - Lubsen, Jacobus

AU - Danchin, Nicolas

AU - Otterstad, Jan Erik

AU - Dunselman, Peter H J M

AU - Kirwan, Bridget Anne

PY - 2011/5

Y1 - 2011/5

N2 - We assessed the independent effects of beta blockers, calcium antagonists, lipid-lowering drugs, angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), anti-platelet drugs, vitamin K antagonists, percutaneous coronary intervention (PCI) and coronary artery by-pass grafting (CABG) on mortality and on the composite endpoint of death, myocardial infarction, stroke or heart failure in patients with stable angina pectoris. We estimated the effects of the interventions used at baseline by multivariate Cox regression and during follow-up by G-estimation in 7,665 patients followed for a mean of 5 years in the ACTION trial. Adjusted hazard ratios (95% confidence intervals) comparing all cause mortality among users during follow-up to non-users were 1.01 (0.91, 1.09) for beta blockade, 0.82 (0.75, 0.89) for ACEIs or ARBs, 0.93 (0.87, 0.98) for calcium antagonists, 0.54 (0.49, 0.62) for lipid-lowering drugs, 0.49 (0.42, 0.53) for anti-platelet drugs, 0.74 (0.69, 0.78) for PCI, and 0.91 (0.82, 0.98) for CABG. Effects on the composite endpoint were less marked. This observational study confirms that ACEIs or ARBs, lipid-lowering and anti-platelet drugs as used in the everyday management of stable angina have independent secondary preventive effects. Calcium antagonists, PCI and CABG also appear to improve outcome.

AB - We assessed the independent effects of beta blockers, calcium antagonists, lipid-lowering drugs, angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), anti-platelet drugs, vitamin K antagonists, percutaneous coronary intervention (PCI) and coronary artery by-pass grafting (CABG) on mortality and on the composite endpoint of death, myocardial infarction, stroke or heart failure in patients with stable angina pectoris. We estimated the effects of the interventions used at baseline by multivariate Cox regression and during follow-up by G-estimation in 7,665 patients followed for a mean of 5 years in the ACTION trial. Adjusted hazard ratios (95% confidence intervals) comparing all cause mortality among users during follow-up to non-users were 1.01 (0.91, 1.09) for beta blockade, 0.82 (0.75, 0.89) for ACEIs or ARBs, 0.93 (0.87, 0.98) for calcium antagonists, 0.54 (0.49, 0.62) for lipid-lowering drugs, 0.49 (0.42, 0.53) for anti-platelet drugs, 0.74 (0.69, 0.78) for PCI, and 0.91 (0.82, 0.98) for CABG. Effects on the composite endpoint were less marked. This observational study confirms that ACEIs or ARBs, lipid-lowering and anti-platelet drugs as used in the everyday management of stable angina have independent secondary preventive effects. Calcium antagonists, PCI and CABG also appear to improve outcome.

KW - Angina pectoris

KW - Cardiovascular agents

KW - Coronary artery bypass

KW - Coronary disease

KW - G-estimation

KW - Percutaneous coronary intervention

KW - Secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=79959737713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959737713&partnerID=8YFLogxK

U2 - 10.1007/s10654-011-9558-5

DO - 10.1007/s10654-011-9558-5

M3 - Article

VL - 26

SP - 375

EP - 383

JO - European Journal of Epidemiology

JF - European Journal of Epidemiology

SN - 0393-2990

IS - 5

ER -